---
layout: post
title: "太极集团子公司盐酸异丙嗪片通过一致性评价"
date: 2022-01-13 16:55:02 +0800
categories: shanghaizhengquanbao·zhongguozhengquanwang
tags: 上海证券报·中国证券网新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.600129" data-code="600129|1|1" data-code2="600129|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.600129&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 600129_0" data-code="K 600129|1|1" data-code2="K 600129|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>太极集团公告，控股子公司西南药业收到国家药品监督管理局关于盐酸异丙嗪片的《药品补充申请批准通知书》，西南药业盐酸异丙嗪片(12.5mg)通过仿制药质量和疗效一致性评价。盐酸异丙嗪片的适应症为皮肤粘膜过敏、晕动症等。<br /></p><p class="em_media">（文章来源：上海证券报·中国证券网）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201132246925393>

[返回上海证券报·中国证券网新闻](//finews.withounder.com/category/shanghaizhengquanbao·zhongguozhengquanwang.html)｜[返回首页](//finews.withounder.com/)